| Line Item | 2025-03-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $4.7M | +112.4% |
| SG&A Expense | $6.9M | +30.7% |
| Operating Income | -$11.6M | +3.7% |
| Pre-tax Income | -$11.4M | +26.0% |
| Income Tax | $0 | — |
| Net Income | -$11.4M | +26.0% |
| EPS (Basic) | -$6.46 | -515.2% |
| Line Item | 2025-03-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $9.1M | +6.1% |
| Current Assets | $9.6M | +2.3% |
| Total Assets | $9.8M | +4.2% |
| Current Liabilities | $1.7M | +119.7% |
| Total Liabilities | $1.7M | -4.0% |
| Stockholders' Equity | $8.1M | +6.2% |
| Line Item | 2025-03-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$8.3M | -24.8% |
| Capital Expenditures | $14K | -26.3% |
| Investing Cash Flow | -$14K | +26.3% |
| Financing Cash Flow | $8.8M | -38.9% |
| Free Cash Flow | -$8.3M | -24.7% |